T-cell Prolymphocytic Leukemia.
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy. T-PLL can be distinguished from other lymphoid diseases by the evaluation and integration of clinical features, morphology, immunophenotyping, cytogenetics, and molecular features. The current therapeutic approach relies on immunotherapy followed by a hematopoietic stem cell transplant in selected cases. Clinical outcomes are generally poor, although insights from genomic and molecular studies may increase our understanding of this disease, with the promise of additional effective therapeutic options.
Department of Haemato-Oncology, The Royal Marsden Biomedical Research Centre, London, UK; Department of Haemato-Oncology, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.
Amit
A
Sud
Department of Haemato-Oncology, The Royal Marsden Biomedical Research Centre, London, UK; Department of Haemato-Oncology, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. Electronic address: Claire.Dearden@rmh.nhs.uk.
Claire
C
Dearden
D064591:Allografts; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D007167:Immunotherapy / Q000379:methods*; D015461:Leukemia, Prolymphocytic, T-Cell / Q000235:genetics / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D015996:Survival Rate
Alemtuzumab; Leukemia; T-cell; T-cell prolymphocytic leukemia